Cell targeting methods and compositions

• US 20040048370A1
• Filed: 06/13/2003
• Published: 03/11/2004
• Est. Priority Date: 06/14/2002
• Status: Active Grant

• Current Assignee: Case Western Reserve University
• Original Assignee: Case Western Reserve University
• Inventors: Cohen, Nir, Dennis, James E., Caplan, Arnold I.
• Granted Patent: US 9,321,992 B2
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C12N 5/0006 Modification of the membrane of cells, e.g. cell decoration
• CPC Class Codes: C12N 5/0655 Chondrocytes; Cartilage

Abstract

In certain aspects, the invention relates to cell delivery compositions comprising a chondrogenic cell and a targeting moiety. Such compositions may be used, for example, in administering a targeted cell therapy to a subject.

Claims

1. A cell delivery composition comprising:

a chondrogenic cell; and

a targeting moiety that interacts with cartilage matrix;

wherein said chondrogenic cell is linked to said targeting moiety.

2. A cell delivery composition of claim 1, wherein said targeting moiety comprises a component of a specific binding pair.

3. The cell delivery composition of claim 1, wherein said targeting moiety comprises an antibody.

4. The cell delivery composition of claim 3, wherein said antibody is a monoclonal antibody.

5. The cell delivery composition of claim 3, wherein said antibody is a polyclonal antibody.

6. The cell delivery composition of claim 3, wherein said antibody is selected from the group consisting of anti-collagen type II, anti-chondroitin 4-sulfate and anti-keratan sulfate.

7. The cell delivery composition of claim 3, wherein said antibody is modified with a hydrophobic moiety.

8. The cell delivery composition of claim 7, wherein said hydrophobic moiety is a palmitoyl moiety.

9. The cell delivery composition of claim 7, wherein said hydrophobic moiety is a myristoyl moiety.

10. The cell delivery composition of claim 1, wherein said targeting moiety comprises a receptor.

11. The cell delivery composition of claim 1, wherein said targeting moiety comprises a ligand.

12. The cell delivery composition of claim 1, wherein said targeting moiety is selected from the group consisting of Fv fragment, single chain Fv (scFv) fragment, Fab′

fragment, F(ab′

)2 fragment, single domain antibody, camelized antibody, humanized antibody, diabodies, tribodies, tetrabodies.

13. The cell delivery composition of claim 1, wherein said targeting moiety comprises an aptamer.

14. The cell delivery composition of claim 1, wherein said chondrogenic cell is linked to said targeting moiety directly.

15. The cell delivery composition of claim 1, wherein said chondrogenic cell is linked to said targeting moiety via a linker.

16. The cell delivery composition of claim 15, wherein said linker is selected from the group consisting of protein G and protein A.

17. A cell delivery composition comprising:

a cell coated with protein G; and

a targeting moiety that binds to a selected tissue.

18. A method of targeting a cell to a specific site comprising:

linking a targeting moiety to said cell; and

wherein said targeting moiety binds to the specific site.

19. The method of claim 18, wherein said targeting moiety is a component of a specific binding pair.

20. The method of claim 18, wherein said targeting moiety comprises an antibody.

21. The method of claim 20, wherein said antibody is a monoclonal antibody.

22. The method of claim 20, wherein said antibody is a polyclonal antibody.

23. The method of claim 20, wherein said antibody is selected from the group consisting of anti-collagen type II, anti-chondroitin 4-sulfate and anti-keratan sulfate.

24. The method of claim 20, wherein said antibody is modified with a hydrophobic moiety.

25. The method of claim 24, wherein said hydrophobic moiety is a palmitoyl moiety.

26. The method of claim 24, wherein said hydrophobic moiety is a myristoyl moiety.

27. The method of claim 18, wherein said targeting moiety comprises a receptor.

28. The method of claim 18, wherein said targeting moiety comprises a ligand.

29. The method of claim 18, wherein said targeting moiety comprises is selected from the group consisting of Fv fragment, single chain Fv (scFv) fragment, Fab′

fragment, F(ab′

)₂ fragment, single domain antibody, camelized antibody, humanized antibody, diabodies, tribodies, tetrabodies.

30. The method of claim 18, wherein said targeting moiety comprises an aptamer.

31. The method of claim 18, wherein said cell is linked to said targeting moiety directly.

32. The method of claim 18, wherein said cell is linked to said targeting moiety via a linker.

33. The method of claim 18, wherein said linker is selected from the group consisting of protein G and protein A.

34. The method of claim 18, wherein said cell is a chondrogenic cell.

35. The method of claim 18, wherein the specific site is cartilage.

36. The method of claim 18, wherein said cartilage is articular cartilage.

37. The method of claim 18, wherein said targeting moiety binds to cartilage matrix.